Show simple item record

dc.contributor.authorMa, Julian K-C.
dc.contributor.authorChristou, Paul
dc.contributor.authorChikwamba, Rachel
dc.contributor.authorHaydon, Hugh
dc.contributor.authorPaul, Mathew
dc.contributor.authorPujol Ferrer, Merardo
dc.contributor.authorRamalingam, Sathishkumar
dc.contributor.authorRech, Elibio
dc.contributor.authorRybicki, Edward
dc.contributor.authorWigdorowitz, Andres
dc.contributor.authorYang, Dai-Chang
dc.contributor.authorThangaraj, Harry
dc.date.accessioned2016-11-17T13:09:27Z
dc.date.available2016-11-17T13:09:27Z
dc.date.issued2013
dc.identifier.issn1467-7644
dc.identifier.urihttp://hdl.handle.net/10459.1/58569
dc.description.abstractMolecular Pharming, the production of recombinant pharmaceuticals through plant biotechnology, has the potential to transform the biologics sector of the pharmaceutical industry. More fascinating however, is how it might be used to improve access to modern medicines, and improve health of the poor in developing countries and emerging economies. Although improving global health through molecular pharming has been discussed for at least two decades, little progress has actually been made. In this manuscript, a four point plan is described to maximise the opportunity for molecular pharming to provide solutions. These are (i) to identify and prioritise important drug targets that are relevant to the poor; (ii) to support research and development partners in low to middle income countries to develop local expertise, transfer technology and build capacity; (iii) to increase collaboration between regulatory bodies to enable national regulatory frameworks to be developed in low to middle income countries; and (iv) to promote intellectual property management approaches that include socially responsible licensing. An existing case study is described to illustrate how this might be achieved.ca_ES
dc.description.sponsorshipThis work was supported by the European COST Action on Molecular Farming (FA804), the EU FP7 project—Access to Pharmaceuticals (ATP) and the ERC Future-Pharma Project. Julian Ma’s research group is also grateful to The Hotung Foundation, The Bill and Melinda Gates Foundation and The Wellcome Trust. Research at the Universitat de Lleida is supported by MICINN, Spain (BIO2011-23324; BIO02011-22525; BIO2012-35359; PIM2010PKB-00746); EU FP7 project SmartCell; EU Framework 7 ERC IDEAS Advanced Grant -BIOFORCE; Research at EMBRAPA is supported by the National Council for Scientific and Technological Development, Coordination for the Improvement of Higher Education Personnel (CAPES), Fundacao de Apoio a Pesquisa and Embrapa Genetic Resources and Biotechnology, Brazil. Work at Bharathiar University is supported by UKIERI, DST-FIST, UGC-SAP.ca_ES
dc.language.isoengca_ES
dc.publisherWileyca_ES
dc.relationMICINN/PN2008-2011/BIO2011-23324ca_ES
dc.relationMICINN/PN2008-2011/BIO2011-22525ca_ES
dc.relationMICINN/PN2008-2011/BIO2012-35359ca_ES
dc.relationMICINN/PN2008-2011/PIM2010PKB-00746ca_ES
dc.relation.isformatofReproducció del document publicat a https://doi.org/10.1111/pbi.12127ca_ES
dc.relation.ispartofPlant Biotechnology Journal, 2013, vol. 11, núm. 9, p. 1029-1033ca_ES
dc.rights(c) Wiley, 2013ca_ES
dc.subjectMolecular pharmingca_ES
dc.subjectResource-poorca_ES
dc.subjectLow incomeca_ES
dc.subjectDeveloping countriesca_ES
dc.titleRealising the value of plant molecular pharming to benefit the poor in developing countries and emerging economiesca_ES
dc.typearticleca_ES
dc.identifier.idgrec021070
dc.type.versionpublishedVersionca_ES
dc.rights.accessRightsinfo:eu-repo/semantics/restrictedAccessca_ES
dc.identifier.doihttps://doi.org/10.1111/pbi.12127
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/FP7/222716ca_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/FP7/232933
dc.date.embargoEndDate2025-01-01


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record